Evaluation of dosing strategy for pembrolizumab for oncology indications

by Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Published 2017-05-01

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects...

by Mark Forman, John Palcza, Jack Tseng, Julie A. Stone, Brittany Walker, Dennis Swearingen, Matthew D. Troyer, Marissa F. Dockendorf
Published 2019-09-01

Immunogenicity of pembrolizumab in patients with advanced tumors

by Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater
Published 2019-08-01